studies

HEPATOLOGY, VOLUME 62, NUMBER 1 (SUPPL) AASLD ABSTRACTS 447A
*all from bilirubin increase
**AFP reduction from baseline of ≥20% AFP or ≥50% AFP in
patients with baseline value ≥20ng/mL
Disclosures:
Robin K. Kelley - Advisory Committees or Review Panels: Acceleron Inc.; Consulting:
Eli Lilly & Co., Acceleron Inc.; Grant/Research Support: Exelixis, Inc.,
Celgene Corp., Eli Lilly & Co., Regeneron Pharmaceuticals, Tekmira Pharmaceuticals,
Novartis, Sanofi
Norah Terrault - Advisory Committees or Review Panels: Eisai, Biotest; Consulting:
BMS, Merck, Achillion; Grant/Research Support: Eisai, Biotest, Vertex,
Gilead, AbbVie, Novartis, Merck
The following authors have nothing to disclose: Varun Saxena, Neil Mehta, K.
Pallav Kolli, Robert Kerlan, Francis Y. Yao, Albert Chang
two groups (P = 0.666). Multivariate analysis identified ICG
R and solitary tumor as independent factors associated with
disease-free survival. Conclusion: The two treatment modalities
attained similar survival benefits in the management of initial
recurrent HCC after curative treatment. In addition to host and
tumor factors, time from primary HCC development to recurrence
was a prognostic factor for recurrence of HCC.
Disclosures:
Kazuaki Chayama - Consulting: AbbVie; Grant/Research Support: Ajinomoto,
Astellas, Asuka, Bayer, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen,
Kowa, Mitsubishi Tanabe, MSD, Eli Lily, Nippon Kayaku, Nippon Shinyaku,
Otsuka, Roche, Takeda, Toray, Torii, Tsumura, Zeria; Speaking and Teaching:
Eisai, Ajinomoto, AbbVie, Abott, Astellas, AstraZeneca, Asuka, Bayer, BMS,
Chugai, Daiichi Sankyo, Dainippon Sumitomo, J&J, Jimro, Miyarisan, MSD,
Nihon Kayaku, Olympus
The following authors have nothing to disclose: Takayuki Fukuhara, Hiroshi
Aikata, Fumi Shinohara, Norihito Nakano, Yuki Nakamura, Masahiro Hatooka,
Kei Morio, Tomoki Kobayashi, Yuuko Nagaoki, Tomokazu Kawaoka, Masataka
Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami
472
Survival analysis of second hepatectomy versus radiofrequency
ablation for initial recurrent small hepatocellular
carcinoma after curative treatment
Takayuki Fukuhara, Hiroshi Aikata, Fumi Shinohara, Norihito
Nakano, Yuki Nakamura, Masahiro Hatooka, Kei Morio, Tomoki
Kobayashi, Yuuko Nagaoki, Tomokazu Kawaoka, Masataka
Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami,
Kazuaki Chayama; Hiroshima university, Hiroshima, Japan
Background and Aim: Japanese and American clinical practice
guidelines recommend hepatectomy and radiofrequency
ablation (RFA) as curative treatments for small hepatocellular
carcinoma (HCC; ≤ 3 nodules and each ≤ 3 cm in diameter).
However, the algorithms recommended in the above-mentioned
guidelines are for primary HCC, not recurrent HCC. The treatment
algorithm for recurrent HCC is not yet reach consensus.
The aim of this retrospective study is to compare the efficacy
of hepatectomy and RFA as the treatment of initial recurrence
after curative treatment. Methods: The following inclusion criteria
were used: 1) initial recurrent HCC after curative treatment,
2) ≤ 3 nodules and each ≤ 3 cm in diameter, 3) no vascular
invasion and no extrahepatic metastasis, and 4) Child-Pugh
class A or B. From January 2001 to December 2014, one
hundred and ninety two patients who met the inclusion criteria
were evaluated. Patients were divided into 2 groups: second
hepatectomy group (n = 120) and RFA group (n = 72). To overcome
bias due to the different distribution of covariates for the
two groups, a one-to-one match was created using propensity
score analysis. After matching, we compared overall survival
(OS), disease-free survival (DFS) between these groups. Results:
1) After one-to-one matching, there was no significant difference
in clinical backgrounds between second hepatectomy
group (n = 62) and RFA group (n = 62). 2) The rate of OS at
3, 5 and 10 years was 77.1%, 59.0% and 38.9% in the second
hepatectomy group and 85.3%, 58.6% and 35.1% in the
RFA group, respectively. There was no significant difference in
OS between these two groups (P = 0.986). Multivariate analysis
identified several host and tumor factors (age